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1. Abstract 
The use of animals in research is under increasing scrutiny from the general public, 
funding agencies and regulatory authorities. Our ability to continue to perform in-
vivo studies in laboratory animals will be critically determined by how researchers 
respond to this new reality. This Perspectives article summarizes recent and ongoing 
initiatives within ORS and allied organizations to ensure that musculoskeletal 
research is performed to the highest ethical standards. It goes on to present an 
overview of the practical application of the 3Rs (reduction, refinement and 
replacement) into experimental design and execution, and discusses recent guidance 
with regard to improvements in the way in which animal data are reported in 
publications. The overarching goal of this review is to challenge the status quo, to 
highlight the absolute interdependence between animal welfare and rigorous 
science, and to provide practical recommendations and resources to allow clinicians 
and scientists to optimize the ways in which they undertake preclinical studies 
involving animals.   
 
Keywords: preclinical; in vivo; 3Rs; ethics; veterinary clinical trials; orthopaedic; 
review 
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2. Introduction 
The use of laboratory animals remains a critical step in the preclinical evaluation of 
pharmaceuticals, biologics and biomedical devices. There is increasing public opposition 
to the use of laboratory animals, and our ability to continue to use animals in research 
will critically depend on how the field responds to this changing conversation. For many, 
whether veterinarians, physicians or scientists, the arguments made against the use of 
animals resonate, and while we may continue to support the use of animals in research, 
each of us has a particular comfort level regarding what is or is not justifiable in the 
name of medical research. Independent of this individual view there is no place in 
science for ill-designed, poorly executed and inadequately reported studies of any type. 
When these are cell culture studies, they are financially and scientifically unjustifiable; if 
they involve animals, they are also ethically unsound, unacceptable and need to be 
stopped. It is our contention that the best approach to addressing the public’s concerns 
over the use of animals in research is to ensure that the scientific community works 
collectively to regulate itself, and that the steps that are being taken to maintain the 
highest ethical standards are both transparent and consistent.  
 
One of the most significant obstacles to improving the quality of animal research is the 
lack of uniformity in the training that researchers receive before they start their 
research careers. This is then compounded by significant variability in the financial and 
technical resources, including infrastructures, that are available to them on a daily basis. 
Over the next couple of years, this journal will partner with topic experts to produce a 
series of “best practice” articles that will drill down into the specifics of some of the core 
research areas in which animal models play a central role. In parallel, the Orthopaedic 
Research Society (ORS) will provide a new forum for researchers using animal models in 
their research. The goal of the new ‘Preclinical Models’ section 
(http://www.ors.org/preclinical/) is to help the Society’s members design and perform 
animal studies to the highest ethical and scientific standards.  
 
This Perspectives article seeks to summarize recent ORS initiatives relating to the use of 
animals in preclinical research, and to present an overview of the key issues that need to 
be considered when planning animal studies related to musculoskeletal research. The 
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goal is not to provide a complete how-to guide, rather to stimulate the reader’s 
curiosity. Much of what we do as researchers is done because “that is how we were told 
to do it.” When it comes to the use of animals, we are duty bound to challenge the 
status quo and to critically assess our methodology. By providing new tools to educate 
researchers about alternatives to using animals, and by training them on new 
techniques to improve animal study design and technical competence, we hope to fuel a 
grass-roots process that will lead to substantive improvements in both the quality and 
the ethical standards of animal studies in musculoskeletal research worldwide. 
 
3. ORS Initiatives Relating to the Use of Animals in Musculoskeletal Research 
The ORS has long realized the importance of animal models in the research that its 
members undertake. Presentations on animal studies can be seen across almost every 
research theme that comes under the ORS umbrella, both at the Annual Meeting and in 
this journal. Over the last 5 years, there has been a growing demand from the 
membership for improvements in the way that this work is conducted and, in particular, 
presented. With a global membership, ORS attracts researchers from many nations, and 
the regulatory procedures relating to research involving animals vary widely. While it is 
not the purview of the ORS or any other society to dictate the means through which 
countries regulate animal studies, it is entirely appropriate for the Society to expect its 
members, as well as non-members who want to present work at our meetings, to 
ensure that appropriate steps are taken to prevent unnecessary pain, suffering or 
distress, and to follow the central tenet’s of the 3Rs of animal research – reduction, 
refinement and replacement. With this in mind, the Journal of Orthopaedic Research has 
now adopted the ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
guidelines1 as part of the manuscript submission process; this will ensure that 
researchers understand and commit to the guiding principles of ethical animal use, and 
that their methods are clearly reported. The expectation is that by requiring researchers 
to formally commit to meeting ARRIVE requirements, the Society will change the way 
that researchers approach their research. At the same time the Society will provide 
enhanced educational content (through “best practice” papers and through the 
educational offerings of the Preclinical Models section) to equip researchers with the 
tools to be the agents of change themselves, without the need for changes in the 
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national regulatory processes. Ultimately, the use of animals in research is a privilege, 
and like all privileges it comes with responsibility. We are the stewards of the animals 
that we use in research, and we are ethically bound to ensure that the procedures that 
are performed on these animals are justifiable, ethical, performed by individuals with 
appropriate technical skills, and backed up with clinically proven anesthesia and 
analgesic protocols to alleviate unnecessary pain or distress.  
 
Veterinarians and others interested in animal models developed an “animal models” 
research interest group (RIG), and held sessions at both the 2015 and 2016 Annual 
Meetings. In 2015, the RIG held an early morning session entitled “Good and Bad Animal 
Models” was organized and chaired by Dr. Stephan Zeiter of the AO Research Institute in 
Davos.  Speakers included Dr. Christopher Little of University of Sydney and Dr. Karl 
Kirker-Head of Tufts University. A second session, a workshop in the main ORS program, 
was entitled “Animal Welfare in Orthopaedic Research: Focus on Refinement and 
Reduction” and coordinated by Mr. Tim Cooney, a research associate of the University of 
Pittsburgh Medical Center, Hamot and Dr. Laurie Goodrich of Colorado State University’s 
College of Veterinary Medicine. 
 
In 2016, the RIG focused on plans to develop an ORS section dedicated to discussions 
about animal use in musculoskeletal research. As a direct result of that discussion, and 
with the support of members at the RIG, plans were enacted to develop a new ORS 
section. The new ‘Preclinical Models’ section is the third to be approved by the ORS 
Board of Directors, following the paths taken by the very successful ‘Spine’ and ‘Tendon’ 
sections. Initially, the section will meet at the Annual Meeting, but future plans include 
the development and deployment of educational content online, through symposia and 
at hands-on laboratories that will provide trainees and more senior researchers with 
cutting-edge skills for performing animal research. It is our hope and expectation that 
the Preclinical Models section will provide a resource to the entire scientific community - 
a place where researchers can seek and offer advice, discuss the pros and cons of animal 
models for a particular research question, identify mentorship and training 
opportunities, and participate in seminars and laboratories to develop and hone new 
technical skills.   
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4. Evolution of the 3Rs and Implications for Musculoskeletal Research  
 In 1959 Russell and Burch published their seminal book on ethical experimentation.2 
Since then the use of the term the “3Rs”, referring to the replacement, reduction and 
refinement of animal experimentation, has been the foundation for high quality and 
humane scientific research. Continued understanding and implementation of the 3Rs is 
essential for acceptance of orthopaedic studies using animals. There are multiple 
resources available to help in the understanding of alternatives for animal research. 
Organizations from around the world have an online presence that can help with the 3Rs 
and alternatives. A good site for locating centers is http://caat.jhsph.edu/resources/. 
The following is a brief introduction to the 3Rs. 
 
Replacement is the most commonly cited of the 3Rs. The goal of replacement is to use 
alternatives to animals in research whenever possible. Examples include the inclusion of 
human volunteers, tissues and cells, mathematical and computer models, using 
established animal cell lines, invertebrates, or immature forms of vertebrates. An 
example of the replacement of animal models is the development of a robotic 
manipulator to simulate clinical tests and gait on cadaveric joints.3 In this study, joint 
biomechanics were first defined in human subjects and then modelled in a robotic 
simulator. Similarly mathematical models generated from in-vivo data can also be used 
for studying mechanical force patterns. Finite element modelling of bone, for example, 
has been used to explore the cause of hip injuries.4 The successful integration of 
mathematical or robotic models depends on the availability of valid data to inform the 
model, and these necessarily come from animals or humans in the first instance. The 
real strength of computational models lies in their use for parametric studies, where the 
goal is to isolate single variables (e.g. to study the influence of pre-tensioning on the 
behaviour of ACL grafts).  For more complex studies, especially those involving biological 
processes such as healing or tissue remodelling, it is impossible to replicate the in vivo 
environment and animal studies of some type are still needed.  
 
Another area of important advancement in replacement is the use of less sentient 
species. Zebrafish and insects are rapidly expanding the horizon for research models in 
multiple fields. This includes orthopaedic research involving tendon, muscle, and bone.5-
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7 Conceptually the replacement of a mammalian species with fish and insects would lead 
to less pain and distress and thus is considered to be more humane, although it should 
be noted that we understand little of pain perception in fish and insects at the current 
time, making this an topic of ongoing debate. 
 
Reduction, the second R, seeks to minimize the number of animals used in an 
experiment. This typically relies on statistical analysis to justify the number of animals 
used in the experiment. Although difficult to estimate for many studies, there is enough 
historical data on experimental variables that determining the power of an experiment 
should be readily achievable. It is important to be mindful of the fact that power 
calculations have limited validity – they relate to a specific model and to a specific 
outcome measure. This underpins the importance of researchers fully disclosing their 
methods. If complete details are provided, other researchers can duplicate the test 
methods and use the existing data to support a new power analysis. Reduction of 
animals can also include sharing of animals between research groups. An example of this 
is the joint publications examining the outcome of high fat diet and exercise on a variety 
of systems. The primary investigator was interested in renal disease associated with 
diabetes, and was willing to share the musculoskeletal system for use by another 
investigator.8, 9 This sharing of tissues halved the number of animals required if the 
studies would have been performed separately. Investigators should take full advantage 
of these and similar opportunities.  
 
Refinement, the third R, refers to strategies designed to minimize the pain, suffering, or 
distress experienced by animals. In orthopaedic research, surgical interventions are 
common and can most frequently benefit from refinements. Refinement can be enacted 
at multiple steps of the process – by ensuring that the surgical team is technically 
proficient in the procedure that is to be employed; by having trained personnel 
assessing animals in the post-operative period; and through the mandatory use of 
proven anesthetic and analgesic agents to control post-procedural pain. One frequently 
articulated concern of the research teams is that addition of an analgesic during a 
procedure may alter the biologic process that is being studied. However, pain and 
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distress also can lead to alterations in healing responses,10 compromising the quality of 
the science. It is our position that analgesics of some form should always be 
administered when invasive procedures are performed on animals. When considering 
the use of analgesics, investigators should be aware of the current use in humans so as 
to best model possible translational opportunities.  
 
The need to improve the design, conduct and analysis of research using animals is an 
ongoing process, with increasing emphasis from the research community on improving 
animal welfare. It is interesting to speculate on the future of the 3R’s as the need for 
sound scientific research is just as relevant today as it was nearly 60 years ago. Since the 
initial description there have been two additional “R’s” that are being proposed as 
essential components of high quality animal research studies. These are Responsibility 
and Reproducibility. Responsibility takes into account the new performance based 
outcomes that should reflect integrity, honesty, and scientific correctness in appropriate 
and reasonable use of laboratory animals.11  Reproducibility of research results relates 
to a topic that is touched on earlier in this review – the notion that it is impossible to 
make valid comparisons between studies when the methods used to derive the data 
have not been documented appropriately. Irreproducibility in animal work is 
inconsistent with the tenets of the 3Rs, since we are clearly unable to avoid unnecessary 
duplication of work, let alone ensure reductions in animal use.12 It is also fiscally 
unsound in an era of increasing pressure on research funds. It was recently estimated 
that irreproducibility in preclinical research wastes around $24 billion per year.13  
 
5. Practical Recommendations for Integrating the 3Rs into Musculoskeletal Research  
The re-emergence of the 3Rs as a fundamental guiding principle for animal research has 
led to the development of emphasis on the practical applications of these principles at 
every stage of design and execution of an animal study. In this section, we will review 
the practicalities of implementing the 3Rs in animal-based research and draw upon our 
collective experience to support this approach and explain why attention to the 3Rs is so 
important. 
 
5.1. Experimental Design 
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The starting point when considering any experimental design is to understand the 
specific question that is being asked, and the most relevant outcome measures that are 
to be reported. Is the study intended as a proof of principle study to determine technical 
feasibility or biological activity, or is it a pivotal preclinical study for the purpose of 
regulatory submission? Have data been collected from animal models prior to this 
study? Where do the gaps in knowledge lie? The answers to these questions will impact 
the choice of animal, the complexity of the experimental matrix, and the selection of an 
appropriate sample size for the study. The choice of outcome measures will ideally be 
based on clinical and translational relevance, but will also be influenced by the 
availability of resources, the technical expertise of the research team, and the budget 
that is available. Non-invasive imaging, which plays such a critical role in clinical and 
preclinical orthopaedics, offers tremendous opportunities for both refinement and 
replacement of animals. However, the trade off is that the instrumentation can be 
expensive to purchase and maintain, while the interpretation of the large and typically 
complex datasets can be technically challenging and time consuming 
 
One of the core elements of the ethical review process is the avoidance of unnecessary 
duplication, but some degree of duplication will often be necessary in order to ensure 
relevance and validity of the data. Pilot studies, for example, are intended to develop 
preliminary data and methods; the same overall experimental design may then be used 
for a larger follow-up study that will expand on the early data and provide appropriate 
statistical power for data analysis. Duplication of an existing technique is both necessary 
and to be encouraged in most cases since the use of an accepted and well characterized 
animal model will help to reduce the problem of irreproducibility that currently 
complicates the interpretation of animal studies from different laboratories and 
different countries. Over time, the adoption of standardized methodologies and 
improved reporting mechanisms will make it easier to compare the results from new 
therapy against those from therapies that have already been evaluated in the same 
model. This will improve the accuracy of sample size calculations (which are commonly 
based on published data) and, as importantly, it may make it possible to reduce overall 
animal use since comparisons could be made against historical data from earlier studies.  
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The best approach to avoiding duplication is to remain current with the latest 
developments in the field of research, through the reading of the latest research articles 
and attendance at meetings. A detailed and up to date literature review should be 
performed, not just to meet the requirements of the ethical review process but also to 
challenge and encourage the researcher to consider refinements in the experimental 
technique, perhaps through the use of cutting-edge imaging. In addition, with the 
explosion of online resources and social media networks, it is easier then ever to 
connect to other investigators in the field and to ask for advice regarding model 
selection. As an example, the veterinary division of AO (www.aovet.aofoundation.org) 
has recently launched an initiative to develop an online, searchable database for 
orthopaedic animal models [Kirker-Head C, personal communication]. In the long term, 
care taken at this early point in study development will help to ensure that the model 
selection and technical procedures are acceptable to the research community and less 
likely to encounter challenges as they come to peer review for presentation and 
publication. 
 
5.2. The Pilot Study 
It is impossible to overstate the benefits of a pilot study and its potential positive impact 
on the quality of the final research product. Pilot studies provide an opportunity to 
evaluate every aspect of the study, from anesthesia and surgery, through post-operative 
care to the collection of both in-life and post-mortem endpoint data. The benefits are 
perhaps most obvious when performing complex procedures or experiments where a 
multidisciplinary team may need to learn to function efficiently together. However, the 
impact can be equally significant in experiments where a new drug is being evaluated in 
an established model, offering an opportunity to refine and validate standard operating 
procedures for drug preparation, administration and the identification of anticipated or 
unanticipated treatment-related side effects. Many institutional animal care and use 
committees (IACUCs) actively encourage the use of pilot studies because of the likely 
benefits of practice in everything that we do, and because the inclusion of a pilot study 
signals the willingness of the investigators to evaluate, refine and confirm their 
procedures ahead of large-scale animal use. 
 
  11 
5.3. Time Points and Outcome Measures 
In most cases, the selection of time points for a specific experiment will be based on 
personal experience, published regulatory guidelines, or a review of previous published 
data. However, in instances where a new outcome measure is proposed, or in which the 
purpose of the study is more mechanistic than end-point based, it is extremely 
important to pay attention to the time points that are to be used. For example, studies 
on a new surface coating or drug therapy to enhance implant fixation may use an end-
point to confirm overall efficacy, but mechanistic information can only come from the 
study of time points that reflect key biological stages in the healing process. It may well 
be that overall fixation of the implant is the same as with a predicate device or 
treatment, but if the rate of healing can be shown to increase, the new approach may 
well have clinical merit in that it will allow patients to return to function earlier. In plain 
terms, the destination may be the same, but if the journey is different then there can be 
clinical impact (positive or negative). Pilot studies can be extremely helpful in this 
regard, allowing for sampling of small numbers of animals at regular time points in order 
to develop descriptive (qualitative) data on the healing process. These data can then 
inform the selection of the most appropriate time points for a larger study that can 
provide objective data on the mechanisms underlying the different healing rate. By 
rationalizing the selection of time points and basing the choices on science rather than 
habit, it is usually possible to achieve significant reductions in overall animal use while 
maximizing the amount of information gleaned from individual animals. As one moves 
from animal to human, it is important to recognize that inter-species differences in 
tissue remodeling rates can significantly impact the translatability of preclinical 
findings,14 but the expectation would be that mechanisms are more conserved between 
species.   
 
The outcome measures used in preclinical animal studies can be broadly classified into 
those with a direct clinical equivalent (e.g. radiography, computed tomography, serum 
or urinary biomarkers, biopsy material) and those that are limited to preclinical research 
(e.g. gross anatomical analysis, mechanical testing. In general, the latter tend to be more 
invasive and/or destructive, while the former tend to be non-invasive or minimally 
invasive and, as a consequence, more feasible for use in human clinical. While it is hard 
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to make definitive recommendations in this area, early-phase studies in rodents and 
rabbits are more likely to make use of invasive testing and intermediate time points with 
terminal evaluations, while pivotal large animal studies are more commonly designed 
with end-points that reflect potential outcome measures that might be of clinical 
interest in early-stage human clinical trials.. The use of a parallel set of outcome 
measures in preclinical and clinical trials offers huge potential value in terms of 
enhancing the translational relevance of the preclinical work; for example, if preclinical 
animal studies can be used to define and validate the relationship between magnetic 
resonance imaging (MRI) appearance and histology for a new cartilage repair strategy, 
the MRI findings from future human clinical trials will be easier to interpret, allowing for 
the use of histopathology as a confirmatory rather than exploratory outcome measure. 
 
5.4. Conducting the Study 
With the move towards the era of large interdisciplinary research teams and “big 
science”, there is a much greater emphasis on inter-disciplinary teamwork in research.15 
As a result, it is commonplace to see investigators from engineering, cell biology and 
medicine working together on an experimental study. There are clear benefits to the 
development of this team-based approach, but it also creates challenges, especially with 
regard to experience in, and attitudes towards, animal research. It is vital that the team 
discusses the logistics of working together on an animal study to ensure that everyone is 
on the same page with regard to experimental design and study conduct. Whenever 
possible, it can be extremely beneficial – we would argue that it should in fact be 
standard practice - to involve an experienced veterinarian as either a co-investigator or a 
consultant to provide input on best practices in drug administration, anesthesia and 
analgesia, post-operative care and euthanasia. It is usually very helpful to engage the 
institution’s animal care staff by presenting an overview of the work, so that they can 
better understand the goals of the work, the potential for complications, and the steps 
that need to be taken to manage those complications.  
 
Whether undertaken under Good laboratory Practice (GLP) guidelines16 or not, it is 
important that every animal procedure is conducted under the umbrella of one or more 
standard operating procedures (SOP). Ideally, the SOPs should be developed following 
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consultation with individuals with prior training and experience with a given procedure; 
the draft SOP can then be evaluated and refined in a pilot study at your institution, and 
the definitive SOP is then used for all future studies. Deviations from the SOP should be 
recorded and reported when the work is presented and published (see below). Use of 
SOPs will reduce variation in procedural methodologies, reduce the number of animals 
needed to achieve statistical power for a given study design and decrease the risk of 
irreproducibility by ensuring that other groups can make use of the same experimental 
design. 
 
5.5. Reporting the Study 
As mentioned previously, the impact of any scientific study can be critically limited by 
deficiencies in experimental design and study execution, but it is often in the reporting 
of the work that the greatest deficiencies are seen. Whether by accident or intent, 
failure to accurately document experimental procedures, post-surgical complications 
and clinical outcome has a significant negative impact on the quality of the resulting 
manuscript. More importantly, it becomes impossible to repeat that experiment, or to 
relate the findings from that study to any other. Taken as a whole, failure to fully 
disclose the research methodologies significantly decreases the translational impact of 
the research because it is impossible for the reader to determine the relevance or the 
robustness of the science. For preclinical science to be relevant, it must be designed and 
conducted appropriately, but it must also be reported and disseminated in an efficient, 
timely and transparent manner. The publication of a set of recommendations regarding 
appropriate reporting of animal research, the ARRIVE guidelines1 represent an important 
step in the right direction. 
 
6. The Ethical Review Process 
The ethical review of scientific research will always be a potentially contentious topic. 
While most if not all agree on the need for oversight, each of us brings personal 
experience and bias (conscious or unconscious) to discussions on this topic. Ethical 
review does necessarily delay researchers who want to be getting on with their 
experiments, but we would argue that appropriate and efficient ethical review is actually 
central to doing great science. If we are to make use of animals in our research, it is our 
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duty (not that of a committee) to ensure that we do so in an ethical and humane 
manner. The purpose of ethical review should be to provide external guidance to 
facilitate this, and of course to identify and block research that is inconsistent with 
ethical and humane principles. The review process therefore needs to be formative, 
timely, unbiased and based on current best practices. The committee charged with 
undertaking ethical review should be approachable, knowledgeable and responsive both 
to investigator needs and to changes in best practices in animal care, veterinary 
medicine and research methodologies. If ethical review functions in this way, it will be 
seen as being a valuable and important part of the process, not an obstacle that one 
must clear before being able to get on with the “real work”.  
 
Although the specific procedures for ethical review vary by country, the primary goal of 
the ethical review process should be to undertake a cost-benefit assessment to 
determine whether it is justifiable to make use of animals for a particular line of 
research. Additionally, steps need to be taken to ensure that investigators are 
appropriately trained and make use of procedures that minimize pain, distress and 
suffering as much as is practical while undertaking their research. The review process 
may be managed centrally by national agencies (such as the Home Office in the UK) or 
locally through institutional structures (such as the Institutional Animal Care and Use 
Committee in the US). Attempts at international harmonization are ongoing,17 but until 
agreement has been reached it has been the policy of most publishers to accept data 
from animal studies as long as there is documentation of appropriate approvals from the 
relevant regulatory agency in the country in which the work was performed. This 
approach generally works well, but there continue to be cases in which authors fail to 
document key steps in the review and approval process, or in which the methods that 
have been approved in one country are inconsistent with best practices in another. 
Adoption of the Arrive guidelines by JOR will be beneficial in ensuring consistency. 
 
7. Recent Initiatives to Increase Transparency in Animal Use  
Two of the most significant developments in recent years have been the publication of 
consensus documents on the reporting of animal experiments (ARRIVE guidelines)1 and 
the introduction of a framework for openness regarding animal testing in the United 
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Kingdom (the Concordat).18 The implications of these documents are far-reaching, and 
while further changes are likely, especially with regard to the Concordat, there is hope 
that they will impact scientific research at a global level. The Journal of Orthopaedic 
Research will soon be implementing the ARRIVE guidelines into the review process for 
any manuscript that reports animal data, and a similar approach is likely to percolate 
down to abstract reviews for conferences. The additional steps required to comply with 
ARRIVE guidelines are not onerous but they provide a transparency that has to date 
been missing and that will significantly enhance the interpretability and impact and 
relevance of the published work. Importantly, the introduction of ARRIVE represents an 
important first step towards reducing the problem of irreproducibility that plagues 
science in general but animal models in particular.12, 13  
 
8. New Strategies to Identify and Manage Pain and Distress in Laboratory Animals 
 
8.1. Behavioral scoring/facial grimace for identification of pain  
Research in musculoskeletal diseases often requires an intervention that has the 
potential to cause pain or distress in laboratory animals. Prevention, detection and relief 
of pain and distress are paramount in performing good scientific studies. This section 
will briefly outline some of the methodology for ensuring animal well being during 
orthopaedic studies. 
 
It is generally understood, and required by regulatory agencies, that pain should be 
prevented or alleviated unless it is part of the scientific study, or it will jeopardize the 
research validity. In the latter case if the investigator is unable to relieve pain or distress 
then the patient should be euthanized. Given that most orthopaedic procedures are not 
examining pain per se, there is rarely a scientific justification for not providing routine 
analgesia, especially if it is administered consistently to all study animals as a matter of 
protocol. There are several analgesic substances available for prevention or treatment of 
pain. Historically the administration of opioids has been the primary treatment given to 
humans for pain prevention post-operatively. However, the development of new 
analgesics has led to the use of multimodal therapy to reduce the side effects of the high 
dose of opioids required for post-operative pain control. Multimodal analgesia is the use 
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of multiple agents to act synergistically for more effective pain control with fewer side 
effects than a single agent. There are several studies that have shown the improved 
efficacy of multimodal therapy. For example the recently approved intravenous 
formulation of acetaminophen (paracetamol) has been shown in combination with 
ketorolac (an NSAID) to improve post-operative pain control compared to either drug 
alone19, 20 In clinical trials, two anticonvulsants, gabapentin and pregabalin, have also 
been shown to be efficacious in reducing post-operative morphine consumption with 
either reduced pain or similar pain levels.21-23 Gabapentin type drugs bind to calcium 
channels in the spinal cord and brain thus reducing afferent excitatory activity. The use 
of these drugs also showed a reduction in side effects.21-23   There are other multimodal 
analgesics that have been shown to improve pain relief, including TRPV1 agonists, 
NMDA receptor antagonists and alpha-2 agonists.24 A review article further identified 
evidence supporting the use of multimodal analgesics for spine surgery. In it they 
suggested that there is good evidence that gabapentinoids, acetaminophen, neuraxial 
blockade and extended-release local anesthetics (in ascending order) reduce 
postoperative pain and narcotic requirements, fair evidence that preemptive analgesia 
and non-steroidal anti-inflammatory drugs (NSAID) result in reduced postoperative pain, 
and insufficient and/or conflicting (Grade I) evidence that muscle relaxants and 
ketamine provide a significant reduction in postoperative pain or narcotic usage.25  
 
Another relatively recent improvement in pain control is the use of pre-emptive 
analgesia. Transmission of pain signals evoked by tissue damage leads to hyperalgesia, 
or sensitization, of the peripheral and central pain pathways. Pre-emptive analgesia is a 
treatment that is initiated before the surgical procedure to reduce this sensitization. The 
goal of pre-emptive analgesia is to stop pain before it starts, thus, preventing the 
physiological consequences of nociceptive transmission evoked hyperalgesia.26, 27 
Several clinical trials have been conducted to assess the impact of pre-emptive analgesia 
versus standard analgesic therapy. Unfortunately, despite the scientific rationale 
supporting pre-emptive analgesia, only NSAIDs have shown a positive effect for reducing 
post-operative pain compared to giving analgesics only post-operatively.27, 28 Although 
no improvement in the short-term was shown with pre-emptive analgesia in all studies, 
there was no evidence that it was more painful. In addition, there is a paucity of 
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information on the control of long-term pain using pre-emptive analgesia. Use of pre-
emptive analgesia is recommended especially in the context of using a multimodal 
analgesia. 
 
One concern specific to musculoskeletal procedures relates to the possibility that 
NSAIDs may effect bone healing. A recent review article examining the clinical evidence 
for this showed that there are conflicting data on the validity of these results.29  Another 
showed there is fair (Grade B) evidence that short-term use of NSAID result in no long-
term reduction in bone healing or fusion rates.25 As the use of NSAIDs is still being 
debated it should be approached cautiously, as it is imperative that the analgesic 
protocol does not affect the scientific results of the animal study. Even if NSAIDs are 
counter indicated another analgesic should be used to provide pain relief.  
 
Current advances with sustained release formulations as well as topical analgesics have 
improved the potential for administration of analgesics to animals without causing 
handling distress. Examples including the topical use of fentanyl either in a patch or a gel 
(Recuvyra) show promise in long-term pain relief.30 In addition, a single injection 
formulation of buprenorphine is available that provides 72 hours of pain relief.31 A 
recent review of the available topical analgesics found that there are a number of new 
analgesics being developed.32 It is clear from this work and the absence of a universal 
analgesic that future analgesic types and combinations are still needed to improve the 
post-operative welfare of patients.33 As these are developed, transferring this 
information to our animal models is essential.  
 
Although in human patients self-administration of analgesics is possible, for our 
experimental animal patients we are required to administer analgesics. Determination 
of pain is not easily performed because they are prey species that have an instinctive 
ability to disguise pain. Thus, it is often only subtle behaviors that will alert the 
investigative team of an animal in potential pain. Careful observation by the animal care 
staff is often the best method for daily assessments of animal well being, as the 
individuals who take care of the animals daily will have knowledge of what is normal 
behavior for the patient. To augment this assessment, though, there are a few 
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behavioral tests that have and are being developed to determine if there is evidence of 
pain. One of these is the use of nest building behavior to assess pain in mice.34 This 
entails addition of a small amount of nesting material into the cage and evaluation of 
whether the mouse incorporates it into the nest. Mice in pain do not perform this task. 
Another assessment used in rodents and other species is the facial grimace score. 
Adapted from children, this scoring system allows assessment of pain based on facial 
features.35, 36 A third potentially exciting new approach involves the use of whole-cage 
monitoring systems to quantify changes in activity patterns within group-housed 
animals.37  
 
9. Objective Measures of Musculoskeletal Functional Recovery  
In a review paper of this type, it is impossible to provide details on all aspects of 
objective evaluation of musculoskeletal function. This section will present an overview 
of some of the common outcome measures and some thoughts on how they may be 
usefully applied to preclinical studies. The main application of the 3Rs in this context is 
the reduction of animal numbers as well as animal suffering. Furthermore, species 
selection plays an important role since their level of development, size, trainability and 
cooperation with the human handlers will impact evaluation methods.  
 
9.1. Non-invasive diagnostic imaging methods  
In musculoskeletal research the benchmark for assessing recovery is usually composed 
of diagnostic imaging modalities, such as plain radiographs, computed tomography (CT), 
magnetic resonance imagine (MRI) and magnetic resonance (MR) spectroscopy, 
scintigraphy, ultrasound and fluoroscopy. All of these methods have the advantage that 
they allow non-invasive evaluation of the target of assessment over time. For quality and 
reasons of restraints animals normally have to undergo general anesthesia for these 
procedures, except for possibly radiographs, standing MRI in horses38 and modern 
fluoroscopy, where ambulation with weight bearing can be visualized.39 In these 
situations sedation may be required depending on individual animal behavior.  It is 
imperative that SOPs are used to standardize data collection so that datasets that can be 
compared between and within animals over time.  
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Although diagnostic imaging offers tremendous possibilities, caution is required for 
interpretation of results, especially if biomaterials, such as calcium phosphate cements 
or metallic implants are used. The latter cause artifacts in the immediate environment of 
CT images and complicate the interpretation of the material to bone-contact-interface 
(BIC).40 The use of high-field MRI can also be problematic with metal implants due to 
concerns about implant migration and possible local heating effects. Materials consisting 
of calcium aggregates also deliver dubious results in CT scans, since the equipment 
cannot distinguish between hydroxyapatite of natural bone or calcium scaffolds 
/matrices. In addition, results are also dependent on the general threshold of calcium 
detection set for the scans. Therefore, CT scans used for detection of new bone 
formation or material resorption should be combined with histology of non-decalcified 
bone samples.  
 
MRI has the advantage of showing soft tissue structures and can be applied for almost 
all aspects of musculoskeletal research. However, one has to keep in mind that the 
power of the MRI equipment may determine the successful detection of treatment 
differences. For example, a 1.5 Tesla MRI was not reliable for interpretation of changes 
of hyaline cartilage,41 while 3 or 7 Tesla equipment was more suitable. Spectroscopy can 
also deliver valuable information about type of tissue molecules (proteoglycan, fat, 
etc.).42 Ultrasound is feasible for screening tendons for signs of degenerations, ruptures, 
or fluid accumulation within soft tissue and is routinely used in horses.43 
 
9.2. Minimally-invasive Assessment and Sampling  
Arthroscopy is the most prominent method for “second-look” evaluations in joints 
following imaging procedures above. The procedure gives direct visualization under 
good illumination and high magnification, while also allowing for biopsies. Research 
projects examining cartilage resurfacing can benefit greatly from arthroscopy.44 If 
performed correctly, arthroscopy results in minimal damage and does not severely 
disturb the overall course of healing/degeneration of hyaline cartilage or other 
associated joint structures.  
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Serial biopsies are a good method to assess functional outcomes following surgery and 
are easily performed in most cases as long as the biopsy material is removed in a 
manner (and from a location) that does not negatively influence healing and remodeling 
of the residual tissue. The same is true for sampling synovial fluid over time with 
repeated punctures. However, it has to be kept in mind, that even with these minimally 
invasive methods perioperative inflammation is produced within the joint structure and 
therefore, these procedures should be temporally spread apart, such that results are not 
artefactually influenced by the previous procedures. 
  
9.3. Biomechanical Methods 
When considering biomechanical testing, it has to be determined whether tests are to 
be performed in vivo, potentially with multiple time points, or whether tests are 
conducted post-mortem to provide only a single time point. This will likely depend on 
what data you are trying to capture and the equipment available to the investigator. By 
combining multiple methods a global picture of the structural and material properties 
can be obtained. 
 
Kinetic analysis of ground reaction forces, whether by traditional force plate or the more 
recently developed pressure-sensitive walkways,45 provides for objective functional 
assessment of overall limb use. Combining kinetic outputs with kinematic data, obtained 
from motion capture systems, allows for real-time monitoring of changes in both limb 
use (overall loading) and limb function (changes in range of joint motion).46 These 
combined data can then be imported into commercial or open source simulation 
software such as OpenSim to allow for the calculation of joint loads and the 
development of mathematical models of joint function.47 Muscle activation during 
activity can also be determined by means of electromyography (EMG) using either 
invasive (needle electrodes) or surface recording.  
 
Advances in microsensor and telemetry technology are now making it possible to obtain 
real-time output from tissues or implants in vivo. For example, strain gauges implanted 
in/on tissues or around joints can be used to record functional loads in vivo.48 Although 
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expensive to deploy, these implantable devices allow for real time collection of serial 
data from individual animals, allowing for reductions in overall animal numbers.  
 
Measuring indentation is a method to assess mechanical properties of hyaline cartilage 
and can be performed in vivo or ex vivo.49 Standardization of the method may be tricky 
especially in vivo, since setting the instruments at the correct 90° angle may not always 
be easy. More recently, reference point indentation has been shown to be a robust, 
nondestructive method for obtaining quantitative data on the mechanical properties of 
whole bones.50 
 
Ex-vivo methods of biomechanical testing incorporate mostly measuring tensional, 
compressive and/or shear forces or fatigue of (healed) tissue structures in customized 
settings. The classic example would be a materials testing machine that can test the 
mechanical properties of whole limbs, or individual elements such as bone or tendons. If 
working with biomaterials, removal torque or push-out tests are often used to evaluate 
osseointegration.51 
 
9.4. Histology 
Histology is a valuable tool for assessing functional outcomes after surgical or medical 
treatment. Structural as well as cellular changes can be observed in detail, although one 
has to be aware that it is a two dimensional method that often suffers from limitations 
in terms of sampling frequency, making its general applicability to the tissue as a whole 
more limited. However, these limitations can be offset to some extent through the use 
of stereology, as well as by combining serial sections with 3-dimensional computed 
tomography and/or MRI imaging to provide the third dimension. 
 
The type of histology that is performed will depend on tissue type and whether implants 
are left in situ (e.g. metallic implants). If metallic implants are to be sectioned in situ, 
non-decalcified tissue samples are embedded in a hard epoxy or acrylic resin such as 
polymethylmethacrylate, then sectioned using a bone saw with a diamond band saw.52 
The cut sections are then ground and polished to final thickness (usually 100-150 µm) 
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and surface stained with either toluidine blue or Giemsa. Toluidine blue is a convenient 
histochemical staining to assess new bone and/or cartilage formation. 
 
If thin bone sections are required for studying tissue responses at a cellular level, any 
metal implant will need to be removed. The tissue is embedded in acrylic resin as above, 
then sectioned on a rotary microtome or annular saw. Thin sections allow for the use of 
a broader variety of stains, including toluidine blue, Movat pentrachrome, von 
Kossa/McNeal, hematoxylin eosin, etc. Staining protocols depend on the specific 
question that is being asked. Although possible, immunohistology with plastic sections is 
problematic and is most reliable in bone samples from small rodents and there, 
preferably bone marrow and not cortical bone. Special resins are available, which are 
mostly too soft for sheep bone and make it almost impossible to get reliable and 
repeatable results, especially if cortical bone is involved. 
 
If there are no implants in the tissue, or if removal of the implant is feasible, 
decalcification and processing into paraffin is the preferred technique for bone sections. 
Decalcification is relatively straightforward requiring hours to days depending on the 
bone thickness and density. Immunohistochemistry is frequently unreliable because of 
the fixation and decalcification process, thus having reliable validated antibodies is 
necessary.  
 
Frozen sectioning is technically challenging for bone but feasible for cartilage and soft 
tissues such as muscle, ligament, tendon, or fibrous tissue. Tendon tissue from larger 
animals like the horse may be too dense to get good and reliable frozen sections, thus 
paraffin sections or even plastic sections may be more suitable. For cartilage alone, cut 
off from the calcified zone, frozen sections and paraffin sections are commonly used and 
suitable for most assessments. Also, identification of fat in tissues is best performed on 
frozen sections because xylene leaches out the fat droplets during processing. Other 
techniques for identification of fat have proven successful if frozen tissues cannot be 
used. 
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Immunohistochemical analysis is highly dependent on the antibody. Tissue preparation 
can greatly influence whether an antibody is going to be successful, and simply working 
in western blot analysis is no guarantee that it will also work in tissue sections. Frozen 
sections are often the most reliable for antigen detection, followed by tissues preserved 
in a short (less than 24 hours) exposure to paraformaldehyde, formaldehyde, long 
exposure (greater than a day) in either paraformaldehyde or formaldehyde, and finally 
the least successful are decalcified tissues. Antigen retrieval techniques are also 
available to increase the likelihood of immunohistochemical staining success. 
 
Electron microscopy uses beams with accelerated electrons to study the ultrastructure 
of specimens. Transmission (TEM), scanning (SEM), reflection (REM) and scanning 
transmission electron microscope (STEM) are provide high spatial resolution. Confocal 
light microscope sometimes overlaps with electron microscopy and for each particular 
research question, pilot studies may be needed to determine the most appropriate 
method of analysis. 
 
9.5. Molecular and biochemical methods 
Modern research in the musculoskeletal area also involved methods of molecular 
biology in which DNA, RNA or specific proteins are quantified. The specifics of these 
techniques are well beyond the scope of this review and will not be presented in detail, 
beyond reminding the reader that the isolation of intact, high quality RNA from 
connective tissues can be challenging and requires efficient and rapid processing of 
tissues following collection from the animal. In addition, the low density of cells in soft 
tissues such as tendons and ligaments requires extensive processing for retrieval of the 
DNA and RNA in the vast collagen milieu.  
 
10. Veterinary Clinical Trials as a Bridge between Preclinical Laboratory Animal Studies 
and Human Clinical Trials  
There are many opportunities in the veterinary clinical realm to utilize patients to 1) 
demonstrate efficacy of an orthopaedic surgical procedure or 2) investigate efficacy of a 
non-surgical treatment modality.  Utilizing veterinary patients can potentially bridge the 
gap between studies in preclinical laboratory animal models and human clinical trials, 
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leading to proof of efficacy and benefits for the veterinary population, as well as 
providing a “pathway” for drugs and procedures to be further studied in humans.53  
 
In the veterinary clinical population there are many patients that provide excellent 
examples of a naturally occurring disease where intervention may be very similar to 
those in human patients, including osteoarthritis (OA)54 and bone cancer.55 A challenge 
in this regard is that even within a disease category such as OA, there may be significant 
differences between species in terms of disease onset (acute or chronic), progression 
(weeks verses months), onset of clinical symptoms versus when the disease began, etc.  
If the outcomes of the disease is not understood in depth, this could lead to 
misinterpretations of a disease treatment and false positive or negative results that will 
not translate successfully into human clinical trials.  It therefore is important for the 
clinician scientist evaluating new treatments to be familiar with the current standard of 
care for this condition in human and/or veterinary patients.  
 
Another opportunity in veterinary patients is that issues such as placebo effects are 
much more rare due to the nature of the patient however the evaluator (clinician) can 
certainly be biased.  The evaluators of the treatment should remain blinded to the 
therapy so as to prevent undue bias.  Just like in human clinical trials, the use of 
randomized blinded (it is double-blinded in people) clinical studies is warranted to make 
the results more robust. Cook et al published an article with proposed definitions and 
criteria for reporting time from outcome and complications in veterinary clinical studies 
and strict definitions are described to aid veterinary clinical scientists in using similar 
terminology to human clinical trials.56 
 
When outcome parameters are described in veterinary clinical patients, variability can 
be introduced due to pre-existing issues with outcome assessments.  For example a 
horse is subjectively scored based on a typical 0-5 lameness scale and flexion tests but 
dogs are graded on criteria such as activity, mood, playfulness etc., which also is very 
different from how pain is assessed in humans. While more objective analyses are being 
developed for both the horse and dog in terms of gyroscopic lameness detectors 
(Lameness Locator®)57 and force plate analyses, these outcome parameters are very 
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different to the pain scales utilized in humans, making it very important to select 
outcome measures appropriately. The use of validated survey instruments for assessing 
pain and functional impairment shows considerable promise in this regard.58, 59  
 
Further challenges that are similar to both veterinary and human clinical trials are 
recruiting patients and getting a population that is similar in disease state.  Further, once 
a treatment or procedure is pursued in a veterinary population, the patients are no 
longer in a “controlled” environment.  Study PI’s rely on owners to interpret 
recommendations of how to care for the patients but compliance is not always 
consistent.  A more “hybrid” model has been followed recently in which horses with OA 
were treated and kept within a center for the entire period of assessment.  This 
accomplished several objectives that allowed maximum consistency; a controlled 
environment in which patients had consistent care, access to equipment such as force 
plate analysis and a lameness locator, and the ability to closely monitor responses that 
may otherwise have been missed.60 While this approach may initially seem more 
expensive, the reduction in variability in data collection, combined with the increased 
compliance of study animals means that the overall cost for these hybrid studies may be 
lower than with an outpatient field trial  (Bertone A, Personal communication). 
 
An opportunity that exists in veterinary patients is that the majority of patients are not 
covered by insurance policies therefore owners are often motivated to enter their 
animals onto a clinical trial especially if there is a monetary incentive (to cover some or 
all of their medical expenses). Conversely, a challenge of these studies is that owners 
may be unwilling to participate if there is a possibility that their animal may receive the 
placebo control treatment.  To motivate owners to enter their animals onto a clinical 
study, a crossover design may be an important incentive needed to partake in a trial 
where all animals receive treatment eventually (either at the initiation or following 
treatment with the control).61  As in all clinical trials whether in people or in veterinary 
patients the importance of accurate power analyses cannot be stressed enough.  If these 
studies are underpowered, the value of the conclusions are meaningless and more 
importantly, a potentially effective treatment or surgical procedure is assumed falsely 
effective (dangerous for the patients) or falsely ineffective resulting in a missed 
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opportunity to bring a valuable therapy to fruition.  Biostatisticians that are well versed 
and familiar with biological studies should always be included as valuable team 
members of clinical trials to ensure proper analyses are performed and that there is no 
bias associated with the results. 
 
11. Summary and Conclusions  
Our ability to continue to use laboratory animals in biomedical research is under more 
intense scrutiny than ever before. The balance has shifted so that the burden of 
evidence now lies squarely with the researcher, who must justify the 
clinical/translational relevance of his/her research and demonstrate that the 
experimental methods do not cause undue pain, distress or suffering to the study 
animals. Recent initiatives within the ORS and other allied organizations are intended to 
enhance the training opportunities available to investigators at all career stages, to 
provide a network of researchers capable of mentoring young investigators, and to offer 
timely reviews in the form of white papers on best practices in animal model selection, 
experimental design/conduct, and study reporting. It is our hope that through these 
initiatives, we will be able to demonstrate to the public that orthopaedic researchers 
understand the absolute need to consider and then apply the fundamental principles of 
the 3Rs when undertaking in-vivo research studies in animals.   
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